GlobeNewswire: Foamix, Ltd. Contains the last 10 of 128 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:34:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/25/1989973/0/en/Foamix-Pharmaceuticals-to-Present-at-the-Cowen-and-Company-s-40th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=21078Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference2020-02-25T13:00:00Z<![CDATA[REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cowen 40th Annual Health Care Conference, taking place March 2-4, 2020 in Boston, Massachusetts.]]>https://www.globenewswire.com/news-release/2020/02/18/1986208/0/en/Foamix-Announces-Integrated-Efficacy-Results-from-the-FMX103-1-5-Topical-Minocycline-Foam-Phase-3-Program-for-Rosacea.html?f=22&fvtc=4&fvtv=21078Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea2020-02-18T13:00:00Z<![CDATA[REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced results from an integrated efficacy analysis on the two pivotal Phase 3 clinical trials for FMX103 (minocycline, 1.5% foam) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe papulopustular rosacea in adults. The new data have been presented at the 17th Annual South Beach Symposium in Dermatology held on February 6-9, 2020 in Miami, Florida.]]>https://www.globenewswire.com/news-release/2020/02/06/1981336/0/en/Foamix-and-Menlo-Announce-Shareholder-Approval-of-Proposed-Merger.html?f=22&fvtc=4&fvtv=21078Foamix and Menlo Announce Shareholder Approval of Proposed Merger2020-02-06T18:00:00Z<![CDATA[Transaction on Track to Close in early March 2020 Transaction on Track to Close in early March 2020]]>https://www.globenewswire.com/news-release/2020/02/06/1981037/0/en/Foamix-Announces-Publication-of-Phase-3-Studies-Evaluating-FMX103-for-the-Treatment-of-Papulopustular-Rosacea-in-Journal-of-the-American-Academy-of-Dermatology.html?f=22&fvtc=4&fvtv=21078Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology2020-02-06T13:00:00Z<![CDATA[REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the Journal of the American Academy of Dermatology (JAAD). Studies 11 and 12 were conducted by Foamix to support the New Drug Application (NDA) submission of FMX103 (minocycline, 1.5% foam), which is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe papulopustular rosacea in adults.]]>https://www.globenewswire.com/news-release/2020/01/17/1971985/0/en/Foamix-Announces-OrbiMed-s-Support-of-Merger-with-Menlo-Therapeutics.html?f=22&fvtc=4&fvtv=21078Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics2020-01-17T13:00:00Z<![CDATA[REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders. OrbiMed expressed its support for the transaction in a press release issued on January 16, 2020. Perceptive Advisors LLC, the Company’s largest shareholder, previously signed a voting agreement on November 10, 2019 to vote its Foamix shares in favor of the merger at the meeting.]]>https://www.globenewswire.com/news-release/2020/01/14/1970220/0/en/Foamix-Announces-AMZEEQ-minocycline-Achievement-of-Preferred-Status-on-Express-Scripts-National-Preferred-Formulary-One-of-the-Largest-Commercial-Formularies-in-the-U-S.html?f=22&fvtc=4&fvtv=21078Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.2020-01-14T13:00:00Z<![CDATA[Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies]]>https://www.globenewswire.com/news-release/2020/01/09/1968399/0/en/Foamix-Announces-AMZEEQ-minocycline-Topical-Foam-Available-in-Pharmacies-Nationwide-on-January-13th-for-the-Treatment-of-Moderate-to-Severe-Acne.html?f=22&fvtc=4&fvtv=21078Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne2020-01-09T13:00:00Z<![CDATA[AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launch]]>https://www.globenewswire.com/news-release/2019/11/25/1951938/0/en/Foamix-Pharmaceuticals-to-Present-at-the-Piper-Jaffray-31st-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=21078Foamix Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference2019-11-25T13:00:00Z<![CDATA[REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference, taking place December 2-5, 2019 at the Lotte New York Palace Hotel in New York City.]]>https://www.globenewswire.com/news-release/2019/11/18/1948677/0/en/Foamix-Announces-Enrollment-Completion-of-Phase-2-Acne-Clinical-Trial-for-FCD105-Minocycline-3-and-Adapalene-0-3-Combination-Foam.html?f=22&fvtc=4&fvtv=21078Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam2019-11-18T13:00:00Z<![CDATA[REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of moderate-to-severe acne vulgaris. The trial will evaluate the efficacy and safety of the investigational topical combination foam, which comprises minocycline 3% and adapalene 0.3%.]]>https://www.globenewswire.com/news-release/2019/11/11/1944599/0/en/Foamix-Reports-Third-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=21078Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update2019-11-11T11:00:00Z<![CDATA[Conference Call and Webcast Scheduled for Monday, November 11th at 8:30am Eastern Time Conference Call and Webcast Scheduled for Monday, November 11th at 8:30am Eastern Time]]>